Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin Enacarbil in Restless Legs Syndrome
NCT03053427Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in restless legs syndrome (RLS) comparing Gabapentin enacarbil with Placebo (2 arms). Primary endpoint: International Restless Legs Syndrome Rating Scale Score at 12 weeks. Started Mar 2017; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT03053427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053427.